HIV pill combo fails to slim belly fat in early trial
NCT ID NCT01420523
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether switching to a two-drug HIV treatment (raltegravir plus maraviroc) could reduce belly fat (lipohypertrophy) in people whose HIV was already well-controlled. It included 48 adults on stable HIV therapy for at least 5 years. The study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Pitié Salpétrière
Paris, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Walking groups could shield HIV-Positive latino men from heart disease
- Friends helping friends: a novel social-network strategy to boost HIV prevention
- Decade-Long study aims to unlock liver disease risks in HIV-Hepatitis b patients
- Could HIV and age weaken vaccine protection? study investigates
- Massive HIV database could unlock secrets of Long-Term health
- Can couples counseling curb HIV? new study tests dyadic approach in south africa